| 1 |
Cognitive Working Memory Training (CWMT) in adolescents suffering from Attention-Deficit/Hyperactivity Disorder (ADHD): A controlled trial taking into account concomitant medication effects.
|
|
|
|
In: Psychiatry research, vol. 269, pp. 79-85 (2018)
|
|
BASE
|
|
Show details
|
|
|
| 2 |
Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial
|
|
|
|
In: PMC (2013)
|
|
Abstract:
OBJECTIVE: The purpose of this study was to evaluate atomoxetine treatment effects in attention-deficit/hyperactivity disorder (ADHD-only), attention-deficit/hyperactivity disorder with comorbid dyslexia (ADHD+D), or dyslexia only on ADHD core symptoms and on sluggish cognitive tempo (SCT), working memory, life performance, and self-concept. METHODS: Children and adolescents (10-16 years of age) with ADHD+D (n=124), dyslexia-only (n=58), or ADHD-only (n=27) received atomoxetine (1.0-1.4 mg/kg/day) or placebo (ADHD-only subjects received atomoxetine) in a 16 week, acute, randomized, double-blind trial with a 16 week, open-label extension phase (atomoxetine treatment only). Changes from baseline were assessed to weeks 16 and 32 in ADHD Rating Scale-IV-Parent-Version:Investigator-Administered and Scored (ADHDRS-IV-Parent:Inv); ADHD Rating Scale-IV-Teacher-Version (ADHDRS-IV-Teacher-Version); Life Participation Scale-Child- or Parent-Rated Version (LPS); Kiddie-Sluggish Cognitive Tempo (K-SCT) Interview; Multidimensional Self Concept Scale (MSCS); and Working Memory Test Battery for Children (WMTB-C). RESULTS: At week 16, atomoxetine treatment resulted in significant (p<0.05) improvement from baseline in subjects with ADHD+D versus placebo on ADHDRS-IV-Parent:Inv Total (primary outcome) and subscales, ADHDRS-IV-Teacher-Version Inattentive subscale, K-SCT Interview Parent and Teacher subscales, and WMTB-C Central Executive component scores; in subjects with Dyslexia-only, atomoxetine versus placebo significantly improved K-SCT Youth subscale scores from baseline. At Week 32, atomoxetine-treated ADHD+D subjects significantly improved from baseline on all measures except MSCS Family subscale and WMTB-C Central Executive and Visuo-spatial Sketchpad component scores. The atomoxetine-treated dyslexia-only subjects significantly improved from baseline to week 32 on ADHDRS-IV-Parent:Inv Inattentive subscale, K-SCT Parent and Teacher subscales, and WMTB-C Phonological Loop and Central Executive component scores. The atomoxetine-treated ADHD-only subjects significantly improved from baseline to Week 32 on ADHDRS-Parent:Inv Total and subscales, ADHDRS-IV-Teacher-Version Hyperactive/Impulsive subscale, LPS Self-Control and Total, all K-SCT subscales, and MSCS Academic and Competence subscale scores. CONCLUSIONS: Atomoxetine treatment improved ADHD symptoms in subjects with ADHD+D and ADHD-only, but not in subjects with dyslexia-only without ADHD. This is the first study to report significant effects of any medication on SCT.
|
|
Keyword:
Adolescent; Adrenergic Uptake Inhibitors -- administration & dosage; Adrenergic Uptake Inhibitors -- therapeutic use; Attention Deficit Disorder with Hyperactivity -- drug therapy; Attention Deficit Disorder with Hyperactivity -- physiopathology; Child; Cognition -- drug effects; Double-Blind Method; Dyslexia -- drug therapy; Dyslexia -- physiopathology; Female; Humans; Male; Memory; Propylamines -- administration & dosage; Propylamines -- therapeutic use; Psychiatric Status Rating Scales; Self Concept; Severity of Illness Index; Short-Term -- drug effects; Time Factors; Treatment Outcome
|
|
URL: http://hdl.handle.net/1805/6912
|
|
BASE
|
|
Hide details
|
|
|
| 3 |
Pharmacotherapy and children with autism spectrum disorder: a tutorial for speech-language pathologists
|
|
|
|
In: NLM (2010)
|
|
BASE
|
|
Show details
|
|
|
| 4 |
Steroids for otitis media with effusion: a systematic review.
|
|
|
|
In: Symplectic Elements at Oxford ; Europe PubMed Central ; PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) (2001)
|
|
BASE
|
|
Show details
|
|
|
| 5 |
Treatment of acquired aphasia and epilepsy.
|
|
|
|
In: Developmental Medicine and Child Neurology, vol. 33, no. 9, pp. 834-835 (1991)
|
|
BASE
|
|
Show details
|
|
|
|
|
